MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

2024.03.14
In January 2024, a groundbreaking study spearheaded by Professor Gang An  from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, made its debut in the esteemed journal Haematologica (IF=11.047). The research, titled "MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities" marks a significant advancement in the understanding of multiple myeloma (MM). This comprehensive investigation meticulously analyzes the prognostic impact of MAF translocations, t(14;16) and t(14;20), within the context of MM, shedding light on their independent prognostic significance despite the presence of other chromosomal anomalies. This study not only enhances the scientific community's comprehension of MM's genetic complexity but also paves the way for refining risk stratification and tailoring treatment approaches for affected patients, thereby contributing to the ongoing efforts to improve outcomes in this challenging hematological malignancy.
Acinetobacter spp. Bloodstream Infection in Hematological Patients: A 10-Year Single-Center Study 

Acinetobacter spp. Bloodstream Infection in Hematological Patients: A 10-Year Single-Center Study 

2024.02.28
In November 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Infectious Diseases. The title of the study is "Acinetobacter spp. Bloodstream Infection in Hematological Patients: A 10-Year Single-Center Study". This comprehensive study sheds light on the significant burden of Acinetobacter spp. BSI in hematological patients, emphasizing the complexity of treating these infections in a population at high risk of adverse outcomes.
Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

2024.01.15
The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year's conference. Over the past half-century, this technology has become an indispensable tool in the diagnosis and follow-up of hematological malignancies. Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults, and the detection of Minimal Residual Disease (MRD) plays a crucial role in clinical treatment and prognosis assessment, despite encountering various technical challenges. With the release of two significant expert consensus statements by the European Leukemia Network (ELN) in 2018 and 2021, technical issues related to AML MRD detection by Multiparameter Flow Cytometry (MFC) were discussed, making this research once again the focus of the hematology field.
Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

2024.01.05
Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Ma Jun, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Ma Jun's perspective: